News and Trends 3 Jan 2018 Swiss Biotech Gets $339M to Boost the Development of Drug Addiction Therapies Addex Therapeutics, which develops drugs for neurological disorders, has signed an agreement with Indivior to propel its drug addiction pipeline forward. Addex, a top biotech from Geneva, develops small molecules for the treatment of neurological disorders. Today, the company has announced that a collaboration worth up to $339M (€282M) has been signed with Indivior that will focus on progressing […] January 3, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2018 What Are Clinical Trials and Why Do We Do Them? If you’ve read any of our articles, you’ll have no doubt heard us banging on about clinical trials, Phase I, Phase II, market approval… But what does this all mean? We’ve put together a quick guide to help you through these crucial stages of drug development. To reach a clinical trial, the drug will have […] January 3, 2018 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2017 Biota Beats: Music from the Microbiome Bacteria and music are two completely unrelated concepts for most of us. But not for the group of artists and scientists behind Biota Beats. The iGEM synthetic biology competition gathers teams of enthusiastic students every year in Boston. But this year, it also gathered the bacteria of the participants. The team from Biota Beats asked […] December 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2017 Scientists Find New Immune Target to Stop Progression of Alzheimer’s Scientists have described a new mechanism by which the immune system can drive Alzheimer’s and shown that blocking it can prevent the disease in mice. A study published yesterday in Nature details how a molecule involved in the innate immune response can promote the aggregation of amyloid-β plaques that appear in the brains of patients […] December 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 Israeli Biotech Acquires Microbiome Company to Fight Chronic Liver Disease BiomX has acquired RondinX, expanding its bacterial target discovery platform and adding new microbiome targets for chronic liver disease. BiomX is a company based in Ness Ziona, Israel, developing customized phage therapy to selectively destroy the bacteria that cause diseases ranging from inflammatory bowel disease (IBD) to cancer. The company has just acquired RondinX, another […] December 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 British Gene Therapy Gets a Huge £85M Boost in Series B Orchard Therapeutics has raised a big round of financing to gene therapy options for many rare diseases for which there are no treatments. London-based Orchard Therapeutics has managed to raise £85M (€96M) in Series B, an amount that will certainly give an important boost to its pipeline of gene therapy treatments for rare diseases. The […] December 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […] December 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 Christmas Has Come Early for Nordic Biotechs as a Norwegian Fund Readies €100M Injection Hadean Ventures has closed its first fund, which it will begin to invest in life sciences companies around Europe, particularly in the Nordic region. Hadean Ventures is a VC fund based in Oslo, Norway, with the aim of improving healthcare to help patients that are suffering around the world. The VC has closed Hadean Capital […] December 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2017 How to Deal with Regulations to Get Approval for CAR-T Cells The biotech industry is diving into the field of highly individualized gene and cell therapy products. The first CAR-T therapy has just been approved in the US and other breakthrough technologies like mRNA and CRISPR have a foot in the door. But getting to the market is not straightforward, not only for developers but also for […] December 20, 2017 - 8 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 Belgian Biotech and Roche Take on Neurological and Developmental Disorders Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a G-protein coupled receptor to treat neurological and developmental disorders. Confo Therapeutics is developing a pipeline of G-protein coupled receptor (GPCR)-targeting drugs to address an unmet medical needs. The biotech spun out from the Vrije Universiteit Brussel in 2015 with the backing of […] December 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 This Gene Therapy for Hemophilia Can Reduce Bleeding by 70% UniQure has published clinical data revealing that its gene therapy for hemophilia B is effective for years and lets patients stop weekly replacement therapy. From its headquarters in Amsterdam, uniQure is developing what could be one of the first gene therapies for hemophilia. A publication in the journal Blood yesterday details the results of a […] December 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner Santa Claus is not the only busy one in the weeks leading up to Christmas this year, with Boehringer Ingelheim signing collaborations with Autifony and Evox Therapeutics. In the last couple of days, Boehringer Ingelheim has agreed to collaborate with two exciting British biotechs. On Monday, a deal worth up to €627.5M was agreed with CNS disorders specialist, […] December 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email